NEW YORK – CytoDyn said on Friday that it received Institutional Review Board approval to begin its Phase II basket trial for its CCR5 antagonist leronlimab (PRO 140).
The Phase II trial will investigate the drug in 22 different solid tumors. The trial will enroll up to 30 patients who are CCR5 positive.
The single-arm study is examining the effects of a weekly dose of 350 mg leronlimab in combination with the standard-of-care chemotherapy drug. The primary endpoint of the study will be progression-free survival.